Free Trial

Jumps higher

EQUITIES

Decent buying orders in Estoxx, over 10k cumulative, pushes Bund lower towards the figure at 175.00.

  • Move seems to be led by "Sichuan Clover Biopharmaceuticals Inc. reported a strong immune response in early-stage trials of its Covid-19 shot" (as per Bloomberg)
  • Despite the Equity bid, USD is seeing better buying on the margin.
  • MNI tech resistance in Estoxx is seen at 3538.52 High Nov 30

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.